Fixkoh Airmaster
Fixkoh Airmaster® is a salmeterol/fluticasone dry powder inhaler (DPI) which is therapeutically equivalent to Seretide® Accuhaler® for formulation and device characteristics.1
Fixkoh® (salmeterol/fluticasone) indications
Fixkoh Airmaster® is indicated in adults and adolescents 12 years of age and older.
Asthma
In the regular treatment of asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid is appropriate. In patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β2 agonist, or, patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist. Note: Fixkoh Airmaster® 50 microgram/100 micrograms is not appropriate in adults and children with severe asthma.
Chronic Obstructive Pulmonary Disease (COPD)
For the symptomatic treatment of patients with COPD, with a FEV1 < 60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
Instructions for reporting Adverse Events can be found in the footer of this page. Prescribing information is available here.
Unlock Savings With Fixkoh®
Significant reduction in prescribing spend vs. Seretide® 100, 250 and 500 Accuhaler®2
Equivalence to Seretide® Accuhaler®
Fixkoh Airmaster® is equivalent to Seretide® Accuhaler® in terms of:1
- Active ingredient
- Delivered dose per actuation
- Inhaling technique
- Therapeutic effect and device characteristics
Fixkoh Airmaster® is available in three strengths enabling stepwise dosing and ensuring continuity of care for patients.
Demonstration devices are also available
Device Characteristics
1. Safety lock | 2. Mouthpiece cover
3. Mouthpiece | 4. Base
Implementation Support
We’re here to support you all the way through the implementation process, with formulary application support document, cost calculators for your area, letters as well as materials for both healthcare professionals and patients.
Formulary Review Process:
- Formulary application support document
Request document - Tailored cost-savings report detailing savings for your area
Request report - Pharmacy letter – introduction to formulary
For Healthcare Professionals:
- Product information leaflets
- Demonstration devices for training
Request demo devices
For Patients
- Device demonstration video
- Leaflet with instructions for use
- Letter to explain change in inhaler
- Website
Visit patient site
References
- STADA UK Ltd. 2024. Data on File. Fixkoh Pharmaceutical Development.
- STADA UK Ltd. 2024. Data on File. Based on indicative NHS list prices and IQVIA data. Access date: April 2025.
- NHS England. 2021. Delivering a ‘Net Zero’ National Health Service. Access date: April 2025.
